Skip to search formSkip to main contentSkip to account menu

Gastrointestinal Lipase Inhibitor

Any substance that inhibits gastrointestinal lipase, an enzyme that is involved in the absorption of dietary lipids. Inhibition of gastrointestinal… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.
AIMS To assess the efficacy, pharmacodynamics, safety and tolerability of a range of doses of cetilistat, a novel inhibitor of… 
Highly Cited
2009
Highly Cited
2009
Pharmacotherapy for obesity.
Obesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive… 
2008
2008
Evaluation of Urinary Oxalate Levels in Patients Receiving Gastrointestinal Lipase Inhibitor
Objective: The purpose of this study was to examine the possible effects of a gastrointestinal lipase inhibitor “Orlistat… 
Highly Cited
2007
Highly Cited
2007
Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
Orlistat is an oral inhibitor of gastrointestinal lipase used for weight reduction in obese patients. Although most adverse drug… 
2002
2002
Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients.
Review
2000
Review
2000
Antiobesity pharmacotherapy in the management of Type 2 diabetes
Obesity is a well‐known risk factor for the development of Type 2 diabetes mellitus. The management of the obese diabetic patient… 
1999
1999
Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Orlistat, a gastrointestinal lipase inhibitor, decreases fat absorption and thus it reduces caloric intake. The objectives of… 
1999
1999
Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient
AbstractObjective: We detected markedly decreased cyclosporin blood levels in a heart-transplanted patient after the… 
1998
1998
Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group.
OBJECTIVE To determine the weight-reducing efficacy of orlistat, a novel gastrointestinal lipase inhibitor, and to define the… 
Review
1992
Review
1992
Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin).
Excessive intake of dietary fat contributes to the development and maintenance of both obesity and hyperlipidemia. Inhibition of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)